Scarica l'app Stockscreener
0.00
100.00%
-1.19
Dopo l'orario di chiusura:
1.00
1.00
+
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ORGS Giù?
Forum
Previsione
Frazionamento azionario
Orgenesis Inc Borsa (ORGS) Ultime notizie
Why Orgenesis Inc. (45O) stock remains top rated2025 Investor Takeaways & Expert Approved Momentum Ideas - newser.com
In-Depth 2025 Common Warts Industry Forecast: Plan Your Strategy for 2034 Success - WhaTech
Rising Sexually Transmitted Infection (STI) Rates Propel Growth In Genital Warts Market: Pushing the Bounda... - WhaTech
Will Orgenesis Inc. (45O) stock benefit from infrastructure billJuly 2025 Patterns & Daily Technical Stock Forecast Reports - newser.com
Can Orgenesis Inc. (45O) stock withstand sector downturnsJuly 2025 Summary & Free Long-Term Investment Growth Plans - newser.com
Orgenesis Presents Technology Update To FDA/CBER Experts - AOL.com
Is Orgenesis Inc 45O a good long term investmentFibonacci Retracement Levels & Explosive Trading Portfolio - earlytimes.in
Is Orgenesis Inc. (45O) stock a top pick for value investorsTrade Exit Report & Low Drawdown Trading Strategies - newser.com
Why Institutions Believe Beeyu Overseas Limited Is Undervalued TodayStock Buyback Updates & High Profit Market Tips - earlytimes.in
Orgenesis (NASDAQ:ORGS) and Oragenics (NYSE:OGEN) Critical Contrast - Defense World
Orgenesis Faces Multiple Leadership Resignations in August - MSN
Orgenesis subsidiary Theracell enters $1 million convertible loan agreement By Investing.com - Investing.com South Africa
Orgenesis subsidiary Theracell enters $1 million convertible loan agreement - Investing.com India
Orgenesis Subsidiary Secures Convertible Loan Agreement - TipRanks
Riku Dining Group Ltd sees U.S. IPO of 2.3 million Class A ordinary shares - MarketScreener
LB Pharmaceuticals raises $285 million in US IPO - MarketScreener
Genital Warts Pipeline Outlook 2025: Insights Into Therapies, Research, and Market Potential - Barchart.com
Exclusive-Stablecoin issuer Figure Technologies set to upsize IPO as demand for crypto-related stocks soars, source says - MarketScreener
Orgenesis’s Sharp Swings Define Its High-Risk Biotech Story - Finimize
1.03%
2.67%
Capitalizzazione:
|
Volume (24 ore):